MSLN and ovarian carcinoma: Biotinylated adapters have been employed in conjunction with AdCARs whose antigen-binding domain consists of avidin or streptavidin: biotin-binding immune receptor (BBIR) T cells in combination with biotinylated anti-mesothelin (MSLN) Abs have been shown to possess a potent antitumor activity against MSLN+ ovarian cancer, both in vitro and in vivo (15).